Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC BRAZIL: Durvalumab in Stage III NSCLC
NCT04230408Phase 2Completed
- Sponsor
- Latin American Cooperative Oncology Group
- Start
- Mar 2021
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Latin American Cooperative Oncology Group. Started Mar 2021; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04230408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230408.